Methods and systems for identifying and treating patients with cancers that can bind E-selectin are disclosed. E-selectin-binding cancers are identified by their cell surface expression sialyl Le3 and sialyl Le3 carbohydrate epitopes, and such cancers can be identified by antibodies that bind to sialyl Lea/x, such as HECA-452. Such cancers can be treated with antagonists of E-selectin such as glycomimetic compounds and with immunotherapies targeting the cell surface carbohydrates containing the sialyl Lea/x domains to block and/or disrupt the binding of E-selectin.
